We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Automated Approach Predicts Alzheimer's Disease Risk

By LabMedica International staff writers
Posted on 08 Jul 2019
An automated immunodiagnostic test predicts risk of developing Alzheimer's disease by measuring the level of beta-amyloid (Abeta) in the blood, which accurately reflects the accumulation of this protein in the brain.

Investigators at Lund University (Sweden) have been searching for accurate blood-based biomarkers for Alzheimer disease (AD), which might improve diagnostic accuracy in primary care settings, increase referrals to memory clinics, and aid in screenings for AD trials.

Towards this end, the investigators analyzed plasma and cerebral spinal fluid (CSF) Abeta42, Abeta40, total tau (tau), and phosphorylated tau (P-tau; only in CSF) using Elecsys immunoassays on a Roche Diagnostics cobas e 601 autoanalyzer.

The cobas e 601 module is a fully automated analyzer that uses a patented electrochemiluminescence (ECL) technology for immunoassay analysis. More...
It was designed for both quantitative and qualitative in vitro assay determinations for a broad range of applications (including anemia; bone, cardiac and tumor markers; critical care; fertility hormones; maternal care; and infectious diseases).

For the current study, the investigators used Elecsys immunoassays to analyze blood samples collected from 842 people in Sweden (The Swedish BioFINDER study) and 237 people in Germany. The cerebrospinal fluid (CSF) Abeta42/Abeta40 ratio was used as the reference standard for brain Abeta status.

The mean age of the 842 participants in the first cohort was 72 years, with a range of 59 to 88 years, and 446 (52.5%) were female. For the 237 subjects in the second cohort, mean age was 66 years with a range of 23 to 85 years, and 120 (50.6%) were female. In the first cohort, plasma Abeta42 and Abeta40 predicted Abeta status with an area under the receiver operating characteristic curve (AUC) of 0.80. When adding APOE, the AUC increased significantly to 0.85.

"Previous studies on methods using blood tests did not show particularly good results; it was only possible to see small differences between Alzheimer's patients and healthy elderly people. Only a year or so ago, researchers found methods using blood sample analysis that showed greater accuracy in detecting the presence of Alzheimer's disease. The difficulty so far is that they currently require advanced technology and are not available for use in today's clinical procedures," said first author Dr. Sebastian Palmqvist, associate professor for clinical memory research at Lund University. "The next step to confirm this simple method to reveal beta-amyloid through blood sample analysis is to test it in a larger population where the presence of underlying Alzheimer's is lower. We also need to test the technique in clinical settings, which we will do fairly soon in a major primary care study in Sweden. We hope that this will validate our results."

The study was published in the June 24, 2019, online edition of the journal JAMA Neurology.

Related Links:
Lund University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.